We are live on ! Find out more
OPNT

Opiant Pharmaceuticals, Inc. Common Stock
OPNT

Delisted

OPNT was delisted on the 1st of March, 2023.

Back to rankings

42 hedge funds and large institutions have $47.6M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

46% more capital invested

Capital invested by funds: $32.7M → $47.6M (+$14.9M)

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

20% more funds holding

Funds holding: 35 → 42 (+7)

Holders
42
Holders Change
+7
Holders Change %
+20%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
11
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.13M
2
DAM
DLD Asset Management
New York
+$836K
3
Marshall Wace
Marshall Wace
United Kingdom
+$657K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$628K
5
Morgan Stanley
Morgan Stanley
New York
+$517K

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$676K
2
Wells Fargo
Wells Fargo
California
-$646K
3
Renaissance Technologies
Renaissance Technologies
New York
-$607K
4
MAM
Marquette Asset Management
Minnesota
-$76.9K
5
RCWMU
Rothschild & Co Wealth Management (UK)
United Kingdom
-$37K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
1
Wells Fargo
California
$7.54M -$646K -23,195 -9%
Renaissance Technologies
2
Renaissance Technologies
New York
$6.18M -$607K -21,800 -11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$6M +$1.13M +40,689 +30%
ACA
4
Apis Capital Advisors
New York
$3.7M +$223K +8,000 +8%
Two Sigma Advisers
5
Two Sigma Advisers
New York
$2.77M -$19.5K -700 -0.8%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$2.42M +$208K +7,475 +12%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$2.24M +$628K +22,543 +51%
Two Sigma Investments
8
Two Sigma Investments
New York
$2.15M +$363K +13,012 +25%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.69M – – –
EI
10
EAM Investors
California
$1.51M -$676K -24,275 -35%
Northern Trust
11
Northern Trust
Illinois
$1.27M -$1.34K -48 -0.1%
BlackRock
12
BlackRock
New York
$1.17M +$280K +10,058 +41%
Morgan Stanley
13
Morgan Stanley
New York
$1.15M +$517K +18,547 +117%
PCM
14
Perritt Capital Management
Illinois
$1.08M – – –
PHP
15
Parkman Healthcare Partners
Connecticut
$1.05M +$36K +1,291 +4%
EIM
16
Essex Investment Management
Massachusetts
$1.05M +$180K +6,471 +26%
DAM
17
DLD Asset Management
New York
$1.01M +$836K +30,000 New
Marshall Wace
18
Marshall Wace
United Kingdom
$793K +$657K +23,577 New
B
19
Bailard
California
$546K – – –
State Street
20
State Street
Massachusetts
$404K +$334K +12,000 New
BCM
21
Bridgeway Capital Management
Texas
$350K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$273K +$50.2K +1,800 +28%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$262K +$217K +7,803 New
JP Morgan Chase
24
JP Morgan Chase
New York
$227K +$156K +5,584 +482%
CSS
25
Cubist Systematic Strategies
Connecticut
$216K +$179K +6,417 New
1
2

OPNT Hedge Fund Activity: Q4 2021 in Review

42 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2021, worth a combined $47.6M — up 46% from $32.7M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new OPNT positions and 4 closed out — a net gain of 7 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.13M. The largest seller was EAM Investors, cutting an estimated $676K.

  • 42 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2021, up from 35 in Q3 2021.
  • Funds reported $47.6M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2021, up 46% quarter-over-quarter.
  • 11 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +7 holders.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $1.13M added.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was EAM Investors, an estimated $676K sold.

Based on aggregated 13F filings for Q4 2021.